Press Releases May 21, 2026 07:30 AM

EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference

EDAP TMS SA to Present and Host Investor Meetings at Jefferies 2026 Global Healthcare Conference

By Caleb Monroe EDAP

EDAP TMS SA, a leader in robotic energy-based therapies, announced that its CEO and CFO will present and hold investor meetings at the Jefferies 2026 Global Healthcare Conference. The event aims to showcase the company's cutting-edge Focal One® prostate focal therapy device and discuss its technologies and growth potential.

EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference
EDAP

Key Points

  • EDAP TMS SA specializes in minimally invasive medical devices using ultrasound technology.
  • The company introduced Focal One®, a leading prostate focal therapy system available in Europe and the U.S.
  • Management will present growth strategy and innovation plans at a prominent healthcare investor conference.

, May 21, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference

Company to Present and Host 1x1 Investor Meetings on Thursday, June 4th, 2026

AUSTIN, Texas, May 21th, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present and, together with Ken Mobeck, Chief Financial Officer, will host 1x1 investor meetings at the upcoming Jefferies 2026 Global Healthcare Conference in New York.

Date: Thursday, June 4th

Time: 2:00-2:30 PM ET

Format: Presentation and 1x1 investor meetings

Webcast: https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/mNTgvmem3UJgTk2XzExVDK

The live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website here.

About EDAP TMS SA

A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com/.

Investor Contact
Louisa Smith
Gilmartin Group
[email protected]


Risks

  • Market acceptance and adoption rates of Focal One® and similar advanced medical devices remain uncertain.
  • Regulatory challenges could affect expansion into new indications beyond prostate cancer.
  • Competitive dynamics in medical device and robotic therapy sectors might impact future performance.

More from Press Releases

Verizon declares quarterly dividend on June 4, 2026 Jun 4, 2026 AmperCap Acquisition Company Completes its $125,000,000 Initial Public Offering Jun 4, 2026 Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026 SOLV Energy Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares of Class A Common Stock Jun 4, 2026 NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option Jun 4, 2026